wonder if the company will test this antihistamine in Huntington's and or PD. the drug's mechanisms of action sounded very like dextromethorphan's to me.
I am hoping it will be tested in PD.
and Paula, I find it so interesting that much of the newest info about drugs shows up in the financial sector news long before it is published in mainstream. indication of primary goal/real interest/motivation? or just a better reporting crew?



(copied from an earlier post on Dimebon):

http://neurotalk.psychcentral.com/sh...hlight=dimebon


(I wondered if this antihistamine had any mechanisms of action related to dextromethorphan (which is a morphine analog) whose primary actions for which PD patients use it are its anti NMDA actions(?)...Dimebon is also an NMDA antagonist, and in addition, affects Ca++ and mt permability pores.)

http://hdlighthouse.org/research/tri...nicaltrial.php
" Based on earlier work in Russia, it appears that this drug may regulate calcium homeostasis, prevent pathological opening of the mitochondrial permeability transition pores, and reduce the excitotoxicity of NMDA receptors.

References:

S. Bachurin, E. Bukatina, N. Lermontova, S. Tkachenko, A. Afanasiev, V. Grigoriev, I. Grigorieva, Yu. Ivanov, S. Sablin, and N. Zefirov. "Antihistamine Agent Dimebon As a Novel Neuroprotector and a Cognition Enhancer." Annals of the N.Y. Academy of Sciences 939(June 2001): 425-435.

S. Bachurin, E. P. Shevtsova, E. G. Kireeva, G. F. Oxenkrug, and S. O. Sablin. "Mitochondria as a Target for Neurotoxins and Neuroprotective Agents." Annals of the New York Academy of Sciences 993(May 2003):334-344. "